Cambridge-based precision therapy company, Blueprint Medicines Corporation, is making strides in the development of genomic medicines for a variety of cancers and blood disorders. Its portfolio includes AYVAKIT to treat systemic mastocytosis and gastrointestinal stromal tumors, BLU-263 for the treatment of indolent SM and other mast cell disorders, and Fisogatinib. The company is also developing GAVRETO to treat various solid tumors, BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC), and BLU-451 to manage NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. Blueprint Medicines Corporation has several collaboration and licensing agreements, including partnerships with Genentech, Inc., CStone Pharmaceuticals, and Clementia Pharmaceuticals, Inc. The company, formerly known as Hoyle Pharmaceuticals, Inc., was incorporated in 2008 and changed its name to Blueprint Medicines Corporation in June 2011.